DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 hour ago

ABCL·AbCellera Biologics Inc.

$.
-. (-.%)
High
$5.46
Open
$5.30
Market Cap
1.59B
52W High
$6.51
Low
$5.16
P. Close
$5.20
P/E
-
52W Low
$1.94
Fwd P/E
-7.22
Mean Target
-
Technical Score (1D)
100
BUY
News Sentiment
55
BULLISH
AbCellera Biologics reported a significant Q1 2026 revenue increase, doubling year-over-year to $8.32 million. This growth is partly attributed to positive interim Phase 1 data for their ABCL635 antibody candidate, which demonstrated favorable safety and pharmacokinetic profiles. The advancement of ABCL635 towards Phase 2 trials is a key focus, suggesting a potential pathway for more consistent revenue generation. Investors will be watching for further clinical updates on ABCL635 and how these developments shape AbCellera's long-term business model.
Earnings Summary
AbCellera Biologics Inc. is a biotechnology firm focused on the discovery and development of antibody-based therapeutics, primarily targeting unmet medical needs within the United States. The company's core business centers on identifying and advancing potential drug candidates through preclinical trials, operating within the dynamic Biotechnology sector. In its most recent reported quarters, AbCellera experienced a notable revenue surge in Q4 2025, reporting $44.85 million against an estimate of $6.19 million, a significant beat. This followed a period of fluctuating revenue, with Q3 2025 at $8.96 million and Q2 2025 at $17.08 million. Earnings per share (EPS) have consistently been negative, with Q4 2025 showing a significant improvement, reporting -0.03 against an estimate of -0.1775, a substantial beat. Prior to this, Q3 2025 EPS was -0.19 (miss), Q2 2025 was -0.12 (beat), and Q1 2025 was -0.15 (miss). The company has demonstrated an inconsistent beat/miss pattern for EPS, beating estimates in 2 of the last 4 reported quarters, while revenue estimates were only provided for the last two quarters, with a significant beat in Q4 2025. Looking at the year-over-year trajectory, the Q4 2025 revenue represents a substantial increase compared to prior periods, though direct YoY comparisons are limited by the available data. The company has shown a pattern of significant revenue beats when estimates are available, particularly in Q4 2025, despite ongoing EPS misses in most quarters. Recent news indicates a significant Q1 2026 revenue increase to $8.32 million, doubling year-over-year, partly due to positive interim Phase 1 data for their ABCL635 antibody candidate. This advancement towards Phase 2 trials is a key focus. However, contrasting analyst sentiment exists, with some projecting significant upside while one firm has downgraded the stock to a 'sell' rating. Investors will be watching for further clinical updates on ABCL635 and how these developments shape AbCellera's long-term business model, alongside monitoring the impact of mixed analyst ratings on market perception.

EPS

EstBeatMiss
$-0.23$-0.17$-0.11$-0.06$-0.00Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26
QtrEstActual+/−
Q1'26$-0.20 - -
Q4'25$-0.18$-0.03+83.1%
Q3'25$-0.16$-0.19-17.3%
Q2'25$-0.16$-0.12+26.5%
Q1'25$-0.14$-0.15-5.3%
Q4'24$-0.15$-0.12+20.8%

Revenue

EstBeatMiss
$-2M$11M$25M$38M$51MQ4'24Q1'25Q2'25Q3'25Q4'25Q1'26
QtrEstActual+/−
Q1'26$6M - -
Q4'25$6M$45M+625.1%
Q3'25 - $9M -
Q2'25 - $17M -
Q1'25 - $4M -
Q4'24 - $5M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ABCL Stock Snapshot

ABCL is currently trading at $5.18, giving AbCellera Biologics Inc. a market cap of 1.59B. Today's range spans $5.16–$5.46, with shares opening at $5.30 and moving down $0.02 (0.5%) from the prior close. DailyIQ's technical score sits at 100/100 (BUY) with a news sentiment reading of 55/100.

Over the past year ABCL has traded between $1.94 and $6.51 - the current price is +166.8% off the 52-week low and -20.5% from the high.

The BUY setup for AbCellera Biologics Inc. (ABCL) - 100/100 technical score, neutral sentiment at 55/100, price $5.18 (in the upper portion of its 52-week range) - is notable at a 1.59B market cap in Healthcare. Small-cap Healthcare names with this kind of dual positive alignment are exactly what growth-focused active managers screen for when looking for the next leg of outperformance. Annual range: $1.94–$6.51.

The combination of a BUY technical signal (100/100) and neutral news sentiment (55/100) in a small-cap like ABCL (1.59B, Healthcare) creates the kind of setup that shows up in small-cap momentum screens used by growth-oriented funds. At $5.18 (in the upper portion of its 52-week range in $1.94–$6.51), the stock is not yet crowded — which means the entry risk-reward is better than it will be if the technical and sentiment setup persists and attracts wider institutional attention.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…